NEW YORK (Reuters Health) - Rituximab combined with ribavirin and interferon alpha-2b is a safe and effective treatment for severe refractory mixed cryoglobulinemia vasculitis associated with hepatitis C virus (HCV) infection, according to a pilot study by French researchers reported in the October issue of the Annals of the Rheumatic Diseases.